Fuest Matthias, Mehta Jodhbir S
Department of Ophthalmology, RWTH Aachen University, Aachen, Germany.
Tissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapore.
Taiwan J Ophthalmol. 2021 Apr 24;11(2):113-121. doi: 10.4103/tjo.tjo_12_21. eCollection 2021 Apr-Jun.
Refractive errors are the leading cause of reversible visual impairment worldwide. In addition to the desired spectacle independence, refractive procedures can improve quality of life, working ability, and daily working performance. Refractive corneal lenticule extraction (RCLE) is a relatively new technique, dependent only on a femtosecond laser (FS). This leads to potential benefits over laser-assisted keratomileusis (LASIK) including a quicker recovery of dry eye disease, a larger functional optical zone, and no flap-related complications. SMILE, available with the VisuMax FS (Carl Zeiss Meditec AG, Jena, Germany), is the most established RCLE application, offering visual and refractive outcomes comparable to LASIK. SmartSight (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany) and CLEAR (Ziemer Ophthalmic Systems AG, Port, Switzerland) are two new RCLE applications that received Conformité Européenne (CE) approval in 2020. In this article, we review refractive and visual outcomes, advantages, and disadvantages of RCLE and also report on the latest advances in RCLE systems.
屈光不正为全球范围内可逆性视力损害的首要原因。除了能实现摆脱眼镜的理想效果外，屈光手术还可改善生活质量、工作能力及日常工作表现。屈光性角膜透镜切除术（RCLE）是一项相对较新的技术，仅依赖飞秒激光（FS）。这相较于准分子激光原位角膜磨镶术（LASIK）具有潜在优势，包括干眼疾病恢复更快、功能性光学区更大且无瓣相关并发症。全飞秒激光微小切口基质透镜切除术（SMILE）可通过VisuMax FS（德国耶拿卡尔蔡司医疗技术公司）实现，是目前应用最为广泛的RCLE术式，其视觉和屈光效果与LASIK相当。SmartSight（德国克莱诺施泰姆SCHWIND眼科技术解决方案有限公司）和CLEAR（瑞士波特齐默眼科系统股份公司）是于2020年获得欧洲合格认证（CE）的两种新型RCLE术式。在本文中，我们回顾了RCLE的屈光和视觉效果、优缺点，并报告了RCLE系统的最新进展。
Zotero 插件
